These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24519894)

  • 1. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
    Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
    Cancer Med; 2014 Apr; 3(2):406-15. PubMed ID: 24519894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy.
    Kitsugi K; Kawata K; Noritake H; Chida T; Ohta K; Ito J; Takatori S; Yamashita M; Hanaoka T; Umemura M; Matsumoto M; Morita Y; Takeda M; Furuhashi S; Kitajima R; Muraki R; Ida S; Matsumoto A; Suda T
    Ann Med; 2024 Dec; 56(1):2398725. PubMed ID: 39221763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Huang PW; Chang CF; Hung CY; Hsueh SW; Chang PH; Yeh KY; Chen JS; Chen YY; Lu CH; Hung YS; Chou WC
    Cancer Med; 2019 Sep; 8(12):5554-5563. PubMed ID: 31385456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
    Xue P; Zhu L; Wan Z; Huang W; Li N; Chen D; Hu J; Yang H; Wang L
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1653-60. PubMed ID: 25792009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio
    Chen Y; Liao Y; Lam LM; He L; Tsang YS; Di YS; Liang ST; Xia Q
    Int J Med Sci; 2020; 17(10):1449-1457. PubMed ID: 32624701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.
    Kou T; Kanai M; Yamamoto M; Xue P; Mori Y; Kudo Y; Kurita A; Uza N; Kodama Y; Asada M; Kawaguchi M; Masui T; Mizumoto M; Yazumi S; Matsumoto S; Takaori K; Morita S; Muto M; Uemoto S; Chiba T
    Int J Clin Oncol; 2016 Feb; 21(1):118-25. PubMed ID: 26123314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
    Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
    Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY
    Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg.
    Berger AK; Abel U; Komander C; Harig S; Jäger D; Springfeld C
    Pancreatology; 2014; 14(3):211-5. PubMed ID: 24854617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.
    Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M
    Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.
    Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S
    J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
    Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
    Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy.
    Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
    Pancreas; 2014 Apr; 43(3):411-6. PubMed ID: 24622071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
    Lee Y; Kim SH; Han JY; Kim HT; Yun T; Lee JS
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2009-16. PubMed ID: 22772951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
    Lee BM; Chung SY; Chang JS; Lee KJ; Seong J
    Gut Liver; 2018 May; 12(3):342-352. PubMed ID: 29409306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
    Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
    Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.
    Chen Y; Yan H; Wang Y; Shi Y; Dai G
    Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy.
    Teo M; Mohd Sharial MS; McDonnell F; Conlon KC; Ridgway PF; McDermott RS
    Tumori; 2013; 99(4):516-22. PubMed ID: 24326841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer.
    Liu ZL; Zeng TT; Zhou XJ; Ren YN; Zhang L; Zhang XX; Ding ZY
    Int J Biol Markers; 2016 Dec; 31(4):e395-e401. PubMed ID: 27416842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.